2025 Sponsors

Scimega is a niche Canadian oncology CRO acting in Canada within the context of global cutting-edge oncology trials sponsored by mid-size and smaller biotechs. Skilled in collaborative vendor teaming, Scimega guarantees sponsors the quickest site start-up and highest patient recruitment rate, without sacrificing premium quality data. With an optimal operations design robust enough to address an ever-changing clinical trial landscape, Scimega’s team of Lean Coached oncology experts go above-and-beyond to provide: Local, full-time, permanent hires for exceptional staff quality; An extensive network of Canadian Investigator Sites that frequently emerge among top enrollers, and are activated 50% faster than average for global studies; Optimal site engagement to maximize quality, timely data entry and query resolution; Robust and Lean Scimega methodology and processes are supported by current technology to keep every trial this CRO monitors on the Lean trajectory.

To learn more about the Canadian opportunity or explore an expansion with Scimega, please visit: https://scimega.com/

TD2 provides innovative services for improved and accelerated development of medicines for cancer. Our team has deep experience and understanding in drug development. Preclinical development, combined with regulatory affairs expertise, guides customized clinical trial design and execution. Our capabilities encourage the timely selection of patient populations who are most likely to benefit from a new agent, and the rapid identification of clinically significant endpoints. To learn more, visit www.td2inc.com

MedQIA, WorldCare Clinical and DARC, have come together to form Voiant, the industry’s leading clinical trial imaging solution provider with unparalleled scientific and clinical domain expertise. Voiant’s unique AI-based software platform integrates all aspects of clinical trial imaging, providing biopharmaceutical companies with high-speed delivery of quality clinical endpoint data.

Onc.AI is venture-capital backed company committed to developing robust, clinically validated, imaging-AI powered clinical management solutions focused on immunotherapy optimization. Using patented, radiomic-based AI models, Onc.AI has developed a clinical decision support platform using routine diagnostic imaging scans specifically for planning and guidance of first-line immune checkpoint inhibitors (ICI) treatment plans.

RareCyte provides Precision Biology™ products and services for discovery, translational research and clinical diagnostics. The Orion™ spatial biology platform enables whole-slide highly multiplexed tissue analysis for multiple samples per day. Comprehensive liquid biopsy offerings enable CTC and other rare cell characterization and single cell retrieval for molecular analysis and CDx development.